Skip to main content
Top
Published in: Clinical Pharmacokinetics 10/2005

01-10-2005 | Review Article

Antimicrobial Therapy in Critically Ill Patients

A Review of Pathophysiological Conditions Responsible for Altered Disposition and Pharmacokinetic Variability

Authors: Dr Federico Pea, Pierluigi Viale, Mario Furlanut

Published in: Clinical Pharmacokinetics | Issue 10/2005

Login to get access

Abstract

Antimicrobials are among the most important and commonly prescribed drugs in the management of critically ill patients. Selecting the appropriate antimicrobial at the commencement of therapy, both in terms of spectrum of activity and dose and frequency of administration according to concentration or time dependency, is mandatory in this setting. Despite appropriate standard dosage regimens, failure of the antimicrobial treatment may occur because of the inability of the antimicrobial to achieve adequate concentrations at the infection site through alterations in its pharmacokinetics due to underlying pathophysiological conditions.
According to the intrinsic chemicophysical properties of antimicrobials, hydrophilic antimicrobials (β-lactams, aminoglycosides, glycopeptides) have to be considered at much higher risk of inter- and intraindividual pharmacokinetic variations than lipophilic antimicrobials (macrolides, fluoroquinolones, tetracyclines, chloramphenicol, rifampicin [rifampin]) in critically ill patients, with significant frequent fluctuations of plasma concentrations that may require significant dosage adjustments. For example, underexposure may occur because of increased volume of distribution (as a result of oedema in sepsis and trauma, pleural effusion, ascites, mediastinitis, fluid therapy or indwelling post-surgical drainage) and/or enhanced renal clearance (as a result of burns, drug abuse, hyperdynamic conditions during sepsis, acute leukaemia or use of haemodynamically active drugs). On the other hand, overexposure may occur because of a drop in renal clearance caused by renal impairment. Care with all these factors whenever choosing an antimicrobial may substantially improve the outcome of antimicrobial therapy in critically ill patients. However, since these situations may often coexist in the same patient and pharmacokinetic variability may be unpredictable, the antimicrobial policy may further benefit from real-time application of therapeutic drug monitoring, since this practice, by tailoring exposure to the individual patient, may consequently be helpful both in improving the outcome of antimicrobial therapy and in containing the spread of resistance in the hospital setting.
Literature
1.
go back to reference Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274(8): 639–44PubMedCrossRef Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274(8): 639–44PubMedCrossRef
2.
go back to reference Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999; 115(3 Suppl.): 34–41SCrossRef Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999; 115(3 Suppl.): 34–41SCrossRef
3.
4.
go back to reference Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31 (1 Suppl.): S25–8PubMedCrossRef Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31 (1 Suppl.): S25–8PubMedCrossRef
5.
go back to reference Emmerson M. Antibiotic usage and prescribing policies in the intensive care unit. Intensive Care Med 2000; 26 Suppl. 1: S26–30PubMedCrossRef Emmerson M. Antibiotic usage and prescribing policies in the intensive care unit. Intensive Care Med 2000; 26 Suppl. 1: S26–30PubMedCrossRef
7.
go back to reference Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992; 257(5073): 1050–5PubMedCrossRef Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992; 257(5073): 1050–5PubMedCrossRef
8.
go back to reference Marchese A, Schito GC, Debbia EA. Evolution of antibiotic resistance in gram-positive pathogens. J Chemother 2000; 12(6): 459–62PubMed Marchese A, Schito GC, Debbia EA. Evolution of antibiotic resistance in gram-positive pathogens. J Chemother 2000; 12(6): 459–62PubMed
9.
go back to reference Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7(2): 337–41PubMedCrossRef Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7(2): 337–41PubMedCrossRef
10.
go back to reference Bartley J. First case of VRSA identified in Michigan. Infect Control Hosp Epidemiol 2002; 23(8): 480PubMed Bartley J. First case of VRSA identified in Michigan. Infect Control Hosp Epidemiol 2002; 23(8): 480PubMed
11.
go back to reference Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51 (40): 902 Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51 (40): 902
12.
go back to reference Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22(5): 387–94PubMedCrossRef Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22(5): 387–94PubMedCrossRef
13.
go back to reference Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111(3): 676–85PubMedCrossRef Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111(3): 676–85PubMedCrossRef
14.
go back to reference Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244(5): 379–86PubMedCrossRef Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244(5): 379–86PubMedCrossRef
15.
go back to reference Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113(2): 412–20PubMedCrossRef Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113(2): 412–20PubMedCrossRef
16.
go back to reference Barcenilla F, Gasco E, Rello J, et al. Antibacterial treatment of invasive mechanical ventilation-associated pneumonia. Drugs Aging 2001; 18(3): 189–200PubMedCrossRef Barcenilla F, Gasco E, Rello J, et al. Antibacterial treatment of invasive mechanical ventilation-associated pneumonia. Drugs Aging 2001; 18(3): 189–200PubMedCrossRef
17.
go back to reference Bergogne-Berezin E. Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit. J Chemother 2001; 13 Spec. No. 1(1): 134–49 Bergogne-Berezin E. Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit. J Chemother 2001; 13 Spec. No. 1(1): 134–49
18.
go back to reference Carter AB, Hornick DB. Therapy for ventilator-associated pneumonia. Clin Chest Med 1999; 20(3): 681–91PubMedCrossRef Carter AB, Hornick DB. Therapy for ventilator-associated pneumonia. Clin Chest Med 1999; 20(3): 681–91PubMedCrossRef
19.
20.
go back to reference Antonelli M, Mercurio G, Di Nunno S, et al. De-escalation antimicrobial chemotherapy in critically ill patients: pros and cons. J Chemother 2001; 13 Spec. No. 1(1): 218–23 Antonelli M, Mercurio G, Di Nunno S, et al. De-escalation antimicrobial chemotherapy in critically ill patients: pros and cons. J Chemother 2001; 13 Spec. No. 1(1): 218–23
21.
go back to reference Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122(6): 2183–96PubMedCrossRef Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122(6): 2183–96PubMedCrossRef
22.
go back to reference Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003; 31(2): 608–16PubMedCrossRef Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003; 31(2): 608–16PubMedCrossRef
23.
go back to reference Houghton D. Antimicrobial resistance in the intensive care unit: understanding the problem. AACN Clin Issues 2002; 13(3): 410–20PubMedCrossRef Houghton D. Antimicrobial resistance in the intensive care unit: understanding the problem. AACN Clin Issues 2002; 13(3): 410–20PubMedCrossRef
24.
go back to reference Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001; 14(6): 711–5PubMedCrossRef Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001; 14(6): 711–5PubMedCrossRef
25.
go back to reference McGowan Jr JE. Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S36–43PubMedCrossRef McGowan Jr JE. Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S36–43PubMedCrossRef
26.
go back to reference Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S12–7PubMedCrossRef Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S12–7PubMedCrossRef
27.
go back to reference Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001; 29(4 Suppl.): N135–42PubMedCrossRef Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001; 29(4 Suppl.): N135–42PubMedCrossRef
28.
go back to reference Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31(7): 1908–14PubMedCrossRef Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31(7): 1908–14PubMedCrossRef
29.
go back to reference Himmelberg CJ, Pleasants RA, Weber DJ, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J Hosp Pharm 1991; 48(6): 1220–7PubMed Himmelberg CJ, Pleasants RA, Weber DJ, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J Hosp Pharm 1991; 48(6): 1220–7PubMed
30.
go back to reference John Jr JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24(3): 471–85PubMedCrossRef John Jr JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24(3): 471–85PubMedCrossRef
31.
go back to reference Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338(4): 232–8PubMedCrossRef Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338(4): 232–8PubMedCrossRef
32.
go back to reference Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28(2): 143–60PubMedCrossRef Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28(2): 143–60PubMedCrossRef
33.
go back to reference Hyatt JM, Schentag JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S18–21PubMedCrossRef Hyatt JM, Schentag JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000; 21(1 Suppl.): S18–21PubMedCrossRef
34.
go back to reference Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11(6): 426–39PubMed Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11(6): 426–39PubMed
35.
go back to reference Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42(3): 521–7PubMed Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42(3): 521–7PubMed
36.
go back to reference Schentag JJ. Antimicrobial management strategies for Grampositive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29(4 Suppl.): N100–7PubMedCrossRef Schentag JJ. Antimicrobial management strategies for Grampositive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29(4 Suppl.): N100–7PubMedCrossRef
37.
go back to reference Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26(1): 1–10PubMedCrossRef Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26(1): 1–10PubMedCrossRef
38.
go back to reference Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77(6 Suppl.): 7–11PubMed Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77(6 Suppl.): 7–11PubMed
39.
go back to reference Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38(1): 5–15PubMedCrossRef Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38(1): 5–15PubMedCrossRef
40.
41.
go back to reference MacGowan AP, Bowker KE. Continuous infusion of betalactam antibiotics. Clin Pharmacokinet 1998; 35(5): 391–402PubMedCrossRef MacGowan AP, Bowker KE. Continuous infusion of betalactam antibiotics. Clin Pharmacokinet 1998; 35(5): 391–402PubMedCrossRef
42.
go back to reference Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17(3): 479–501PubMedCrossRef Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17(3): 479–501PubMedCrossRef
43.
go back to reference Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37(5): 1073–81PubMedCrossRef Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37(5): 1073–81PubMedCrossRef
44.
go back to reference Schentag JJ. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 2000; 31 Suppl. 2: S40–4PubMedCrossRef Schentag JJ. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 2000; 31 Suppl. 2: S40–4PubMedCrossRef
45.
go back to reference Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45(10): 2793–7PubMedCrossRef Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45(10): 2793–7PubMedCrossRef
46.
go back to reference Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 Suppl. 1: 6–14PubMedCrossRef Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 Suppl. 1: 6–14PubMedCrossRef
47.
go back to reference Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279(2): 125–9PubMedCrossRef Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279(2): 125–9PubMedCrossRef
48.
go back to reference Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21(10 Pt 2): 233–52SCrossRef Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21(10 Pt 2): 233–52SCrossRef
49.
go back to reference Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40(3): 169–87PubMedCrossRef Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40(3): 169–87PubMedCrossRef
50.
go back to reference Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29–36PubMedCrossRef Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29–36PubMedCrossRef
51.
go back to reference Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115(3 Suppl.): 19–23SCrossRef Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115(3 Suppl.): 19–23SCrossRef
52.
go back to reference Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001; 17(1): 1–8PubMedCrossRef Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001; 17(1): 1–8PubMedCrossRef
53.
go back to reference Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32(8): 1678–82PubMedCrossRef Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32(8): 1678–82PubMedCrossRef
54.
go back to reference Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48(5): 1441–53PubMedCrossRef Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48(5): 1441–53PubMedCrossRef
55.
go back to reference Pea F, Pavan F, Nascimben E, et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003; 47(10): 3104–8PubMedCrossRef Pea F, Pavan F, Nascimben E, et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003; 47(10): 3104–8PubMedCrossRef
56.
go back to reference Pea F, Pavan F, Di Qual E, et al. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500mg bid for ventilator-associated pneumonia. J Chemother 2003; 15(6): 563–7PubMed Pea F, Pavan F, Di Qual E, et al. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500mg bid for ventilator-associated pneumonia. J Chemother 2003; 15(6): 563–7PubMed
57.
go back to reference Boy D, Well M, Kinzig-Schippers M, et al. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400mg) versus ciprofloxacin (500mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004; 23 Suppl. 1: S6–16PubMedCrossRef Boy D, Well M, Kinzig-Schippers M, et al. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400mg) versus ciprofloxacin (500mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004; 23 Suppl. 1: S6–16PubMedCrossRef
59.
go back to reference Vrhovac B, Sarapa N, Bakran I, et al. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 1995; 28(5): 405–18PubMedCrossRef Vrhovac B, Sarapa N, Bakran I, et al. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 1995; 28(5): 405–18PubMedCrossRef
60.
go back to reference Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30(2): 134–44PubMed Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30(2): 134–44PubMed
61.
go back to reference Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet 1993; 24(1): 46–58PubMedCrossRef Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet 1993; 24(1): 46–58PubMedCrossRef
62.
go back to reference Park JM, Lin YS, Calamia JC, et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther 2003; 73(6): 545–53PubMedCrossRef Park JM, Lin YS, Calamia JC, et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther 2003; 73(6): 545–53PubMedCrossRef
63.
go back to reference Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124(1): 73–8PubMedCrossRef Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124(1): 73–8PubMedCrossRef
64.
go back to reference Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980; 87(2): 164–9PubMed Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980; 87(2): 164–9PubMed
65.
go back to reference Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43(7): 726–30PubMedCrossRef Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43(7): 726–30PubMedCrossRef
66.
go back to reference Brunner M, Pernerstorfer T, Mayer BX, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28(6): 1754–9PubMedCrossRef Brunner M, Pernerstorfer T, Mayer BX, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28(6): 1754–9PubMedCrossRef
67.
go back to reference Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29(2): 385–91PubMedCrossRef Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29(2): 385–91PubMedCrossRef
68.
go back to reference Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002; 30(7): 1478–82PubMedCrossRef Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002; 30(7): 1478–82PubMedCrossRef
69.
go back to reference Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43(7): 1798–802PubMed Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43(7): 1798–802PubMed
70.
go back to reference Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179(6): 436–40PubMedCrossRef Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179(6): 436–40PubMedCrossRef
71.
go back to reference McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996; 16(5): 924–31PubMed McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996; 16(5): 924–31PubMed
72.
go back to reference Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996; 22(5): 443–6PubMedCrossRef Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996; 22(5): 443–6PubMedCrossRef
73.
go back to reference Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23(6): 678–82PubMed Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23(6): 678–82PubMed
74.
go back to reference Ronchera-Oms CL, Tormo C, Ordovas JP, et al. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995; 20(5): 253–8PubMedCrossRef Ronchera-Oms CL, Tormo C, Ordovas JP, et al. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995; 20(5): 253–8PubMedCrossRef
75.
go back to reference Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36(3): 679–81PubMedCrossRef Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36(3): 679–81PubMedCrossRef
76.
go back to reference Aldaz A, Ortega A, Idoate A, et al. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 2000; 22(3): 250–7PubMedCrossRef Aldaz A, Ortega A, Idoate A, et al. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 2000; 22(3): 250–7PubMedCrossRef
77.
go back to reference Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intraabdominal infections. J Antimicrob Chemother 2002; 49(1): 121–8PubMedCrossRef Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intraabdominal infections. J Antimicrob Chemother 2002; 49(1): 121–8PubMedCrossRef
78.
go back to reference Romano S, Fernandez de Gatta MM, Calvo MV, et al. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44(2): 235–42PubMedCrossRef Romano S, Fernandez de Gatta MM, Calvo MV, et al. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44(2): 235–42PubMedCrossRef
79.
go back to reference Pea F, Brollo L, Lugano M, et al. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001; 23(5): 587–8PubMedCrossRef Pea F, Brollo L, Lugano M, et al. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001; 23(5): 587–8PubMedCrossRef
80.
go back to reference Sanchez A, Lopez-Herce J, Cueto E, et al. Teicoplanin pharmacokinetics in critically ill paediatric patients. J Antimicrob Chemother 1999; 44(3): 407–9PubMedCrossRef Sanchez A, Lopez-Herce J, Cueto E, et al. Teicoplanin pharmacokinetics in critically ill paediatric patients. J Antimicrob Chemother 1999; 44(3): 407–9PubMedCrossRef
81.
go back to reference Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47(4): 421–9PubMedCrossRef Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47(4): 421–9PubMedCrossRef
82.
go back to reference Mimoz O, Soreda S, Padoin C, et al. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology 2000; 93(3): 735–43PubMedCrossRef Mimoz O, Soreda S, Padoin C, et al. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology 2000; 93(3): 735–43PubMedCrossRef
83.
go back to reference Bonapace CR, White RL, Friedrich LV, et al. Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob Agents Chemother 1999; 43(12): 2848–54PubMed Bonapace CR, White RL, Friedrich LV, et al. Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob Agents Chemother 1999; 43(12): 2848–54PubMed
84.
go back to reference Sampol E, Jacquet A, Viggiano M, et al. Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 2000; 46(2): 315–7PubMedCrossRef Sampol E, Jacquet A, Viggiano M, et al. Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 2000; 46(2): 315–7PubMedCrossRef
85.
go back to reference Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42(6): 589–98PubMedCrossRef Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42(6): 589–98PubMedCrossRef
86.
go back to reference Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43(10): 2559–61PubMed Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43(10): 2559–61PubMed
87.
go back to reference Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003; 97(4): 1149–54PubMedCrossRef Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003; 97(4): 1149–54PubMedCrossRef
88.
go back to reference Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45(3): 329–35PubMedCrossRef Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45(3): 329–35PubMedCrossRef
89.
go back to reference Fernandez de Gatta MM, Fruns I, Hernandez JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993; 12(7): 515–20PubMed Fernandez de Gatta MM, Fruns I, Hernandez JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993; 12(7): 515–20PubMed
90.
go back to reference Le Normand Y, Milpied N, Kergueris MF, et al. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994; 36(1–2): 121–5PubMedCrossRef Le Normand Y, Milpied N, Kergueris MF, et al. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994; 36(1–2): 121–5PubMedCrossRef
91.
go back to reference Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995; 14(8): 667–73PubMedCrossRef Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995; 14(8): 667–73PubMedCrossRef
92.
go back to reference Pea F, Viale P, Candoni A, et al. Acute leukemic patients with febrile neutropenia: a special population benefiting from higher dosing regimen of teicoplanin. Clin Pharmacokinet 2004; 43(6): 405–15PubMedCrossRef Pea F, Viale P, Candoni A, et al. Acute leukemic patients with febrile neutropenia: a special population benefiting from higher dosing regimen of teicoplanin. Clin Pharmacokinet 2004; 43(6): 405–15PubMedCrossRef
93.
go back to reference King CH, Creger RJ, Ellner JJ. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrob Agents Chemother 1985; 27(3): 285–90PubMedCrossRef King CH, Creger RJ, Ellner JJ. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrob Agents Chemother 1985; 27(3): 285–90PubMedCrossRef
94.
go back to reference Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35(4): 696–700PubMedCrossRef Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35(4): 696–700PubMedCrossRef
95.
go back to reference Rybak MJ, Bailey EM, Lamp KC, et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36(5): 1109–14PubMedCrossRef Rybak MJ, Bailey EM, Lamp KC, et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36(5): 1109–14PubMedCrossRef
96.
go back to reference Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25(5): 806–11PubMedCrossRef Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25(5): 806–11PubMedCrossRef
97.
go back to reference Pea F, Furlanut M, Bianchi L. Systemic vancomycin overexposure in a patient with spinal cord injury who had Staphylococcal sepsis and Clostridium difficile colitis. Ther Drug Monit 2000; 22(2): 233–4PubMedCrossRef Pea F, Furlanut M, Bianchi L. Systemic vancomycin overexposure in a patient with spinal cord injury who had Staphylococcal sepsis and Clostridium difficile colitis. Ther Drug Monit 2000; 22(2): 233–4PubMedCrossRef
98.
go back to reference Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40(11): 833–68PubMedCrossRef Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40(11): 833–68PubMedCrossRef
99.
go back to reference Wada DR, Drover DR, Lemmens HJ. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998; 35(1): 1–7PubMedCrossRef Wada DR, Drover DR, Lemmens HJ. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998; 35(1): 1–7PubMedCrossRef
100.
go back to reference Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115(6): 457–69PubMed Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115(6): 457–69PubMed
101.
go back to reference Glauser MP, Zanetti G, Baumgartner JD, et al. Septic shock: pathogenesis. Lancet 1991; 338(8769): 732–6PubMedCrossRef Glauser MP, Zanetti G, Baumgartner JD, et al. Septic shock: pathogenesis. Lancet 1991; 338(8769): 732–6PubMedCrossRef
102.
go back to reference Denaro CP, Ravenscroft PJ. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Aust N Z J Med 1987; 17(5): 526–32PubMedCrossRef Denaro CP, Ravenscroft PJ. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Aust N Z J Med 1987; 17(5): 526–32PubMedCrossRef
103.
go back to reference Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med 1983; 11(12): 948–50PubMedCrossRef Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med 1983; 11(12): 948–50PubMedCrossRef
104.
go back to reference Kloth DD, Tegtmeier BR, Kong C, et al. Altered gentamicin pharmacokinetics during the perioperative period. Clin Pharm 1985; 4(2): 182–5PubMed Kloth DD, Tegtmeier BR, Kong C, et al. Altered gentamicin pharmacokinetics during the perioperative period. Clin Pharm 1985; 4(2): 182–5PubMed
105.
go back to reference Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987; 15(12): 1143–5PubMedCrossRef Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987; 15(12): 1143–5PubMedCrossRef
106.
go back to reference Fuhs DW, Mann HJ, Kubajak CA, et al. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm 1988; 7(3): 207–13PubMed Fuhs DW, Mann HJ, Kubajak CA, et al. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm 1988; 7(3): 207–13PubMed
107.
go back to reference Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest 1989; 95(6): 1295–7PubMedCrossRef Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest 1989; 95(6): 1295–7PubMedCrossRef
108.
go back to reference Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6(2): 148–53PubMed Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6(2): 148–53PubMed
109.
go back to reference Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987; 122(2): 207–12PubMedCrossRef Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987; 122(2): 207–12PubMedCrossRef
110.
go back to reference Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16(4): 327–30PubMedCrossRef Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16(4): 327–30PubMedCrossRef
111.
go back to reference Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988; 16(4): 418–22PubMed Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988; 16(4): 418–22PubMed
112.
go back to reference Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989; 17(2): 154–7PubMedCrossRef Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989; 17(2): 154–7PubMedCrossRef
113.
go back to reference Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16(5): 303–6PubMedCrossRef Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16(5): 303–6PubMedCrossRef
114.
go back to reference Hansen M, Christrup LL, Jarlov JO, et al. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001; 45(6): 734–40PubMedCrossRef Hansen M, Christrup LL, Jarlov JO, et al. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001; 45(6): 734–40PubMedCrossRef
115.
go back to reference De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41(14): 1135–51PubMedCrossRef De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41(14): 1135–51PubMedCrossRef
116.
go back to reference Lipman J, Wallis SC, Rickard CM, et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001; 27(2): 363–70PubMedCrossRef Lipman J, Wallis SC, Rickard CM, et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001; 27(2): 363–70PubMedCrossRef
117.
go back to reference Eid AA, Keddissi JI, Kinasewitz GT. Hypoalbuminemia as a cause of pleural effusions. Chest 1999; 115(4): 1066–9PubMedCrossRef Eid AA, Keddissi JI, Kinasewitz GT. Hypoalbuminemia as a cause of pleural effusions. Chest 1999; 115(4): 1066–9PubMedCrossRef
118.
go back to reference Makino J, Yoshiyama Y, Kanke M, et al. Pharmacokinetic study of penetration of meropenem into pleural effusion in patients with pleurisy. Jpn J Antibiot 2002; 55(1): 77–88PubMed Makino J, Yoshiyama Y, Kanke M, et al. Pharmacokinetic study of penetration of meropenem into pleural effusion in patients with pleurisy. Jpn J Antibiot 2002; 55(1): 77–88PubMed
119.
go back to reference Goonetilleke AK, Dev D, Aziz I, et al. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J Antimicrob Chemother 1996; 38(6): 969–76PubMedCrossRef Goonetilleke AK, Dev D, Aziz I, et al. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J Antimicrob Chemother 1996; 38(6): 969–76PubMedCrossRef
120.
go back to reference Kimura M, Matsushima T, Nakamura J, et al. Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusion. Antimicrob Agents Chemother 1992; 36(12): 2774–7PubMedCrossRef Kimura M, Matsushima T, Nakamura J, et al. Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusion. Antimicrob Agents Chemother 1992; 36(12): 2774–7PubMedCrossRef
121.
go back to reference Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins: time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990; 26 Suppl. A: 1–10PubMedCrossRef Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins: time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990; 26 Suppl. A: 1–10PubMedCrossRef
122.
go back to reference Miglioli PA, Pivetta P, Fantoni U, et al. Penetration of aztreonam into pleural exudate following rapid intravenous bolus or constant infusion. Chemotherapy 1990; 36(5): 321–4PubMedCrossRef Miglioli PA, Pivetta P, Fantoni U, et al. Penetration of aztreonam into pleural exudate following rapid intravenous bolus or constant infusion. Chemotherapy 1990; 36(5): 321–4PubMedCrossRef
123.
go back to reference Limthongkul S, Charoenlap P, Nuchprayoon CJ, et al. Amikacin pharmacokinetics in plasma and pleural fluid. J Med Assoc Thai 1989; 72(2): 90–6PubMed Limthongkul S, Charoenlap P, Nuchprayoon CJ, et al. Amikacin pharmacokinetics in plasma and pleural fluid. J Med Assoc Thai 1989; 72(2): 90–6PubMed
124.
go back to reference Limthongkul S, Poshyachinda M, Charoenlap P, et al. Gentamicin, tobramycin and netilmicin pharmacokinetics in plasma and pleural fluid. J Med Assoc Thai 1988; 71(10): 541–7PubMed Limthongkul S, Poshyachinda M, Charoenlap P, et al. Gentamicin, tobramycin and netilmicin pharmacokinetics in plasma and pleural fluid. J Med Assoc Thai 1988; 71(10): 541–7PubMed
125.
go back to reference Barrueco M, Otero MJ, Garcia MJ, et al. Pleural fluid levels of cefoxitin in patients with renal impairment. Int J Clin Pharmacol Ther Toxicol 1986; 24(9): 485–9PubMed Barrueco M, Otero MJ, Garcia MJ, et al. Pleural fluid levels of cefoxitin in patients with renal impairment. Int J Clin Pharmacol Ther Toxicol 1986; 24(9): 485–9PubMed
126.
go back to reference Benoni G, Arosio E, Cuzzolin L, et al. Penetration of ceftriaxone into human pleural fluid. Antimicrob Agents Chemother 1986; 29(5): 906–8PubMedCrossRef Benoni G, Arosio E, Cuzzolin L, et al. Penetration of ceftriaxone into human pleural fluid. Antimicrob Agents Chemother 1986; 29(5): 906–8PubMedCrossRef
127.
go back to reference Garcia MJ, Otero MJ, Barrueco M, et al. Pharmacokinetics of cefoxitin in patients with pleural effusion on a multiple dosage regimen. Int J Clin Pharmacol Ther Toxicol 1984; 22(6): 300–3PubMed Garcia MJ, Otero MJ, Barrueco M, et al. Pharmacokinetics of cefoxitin in patients with pleural effusion on a multiple dosage regimen. Int J Clin Pharmacol Ther Toxicol 1984; 22(6): 300–3PubMed
128.
go back to reference Lechi A, Arosio E, Xerri L, et al. The kinetics of cefuroxime in ascitic and pleural fluid. Int J Clin Pharmacol Ther Toxicol 1982; 20(10): 493–6PubMed Lechi A, Arosio E, Xerri L, et al. The kinetics of cefuroxime in ascitic and pleural fluid. Int J Clin Pharmacol Ther Toxicol 1982; 20(10): 493–6PubMed
129.
go back to reference Barrueco M, Garcia MJ, Otero MJ, et al. Disposition of cefoxitin in patients with pleural effusion. Clin Ther 1981; 3(6): 425–35PubMed Barrueco M, Garcia MJ, Otero MJ, et al. Disposition of cefoxitin in patients with pleural effusion. Clin Ther 1981; 3(6): 425–35PubMed
130.
go back to reference Joseph J, Vaughan LM, Basran GS. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother 1994; 28(3): 313–5PubMed Joseph J, Vaughan LM, Basran GS. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother 1994; 28(3): 313–5PubMed
131.
go back to reference Walstad RA, Hellum KB, Blika S, et al. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother 1983; 12 Suppl. A: 275–82PubMedCrossRef Walstad RA, Hellum KB, Blika S, et al. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother 1983; 12 Suppl. A: 275–82PubMedCrossRef
132.
go back to reference Teixeira LR, Sasse SA, Villarino MA, et al. Antibiotic levels in empyemic pleural fluid. Chest 2000; 117(6): 1734–9PubMedCrossRef Teixeira LR, Sasse SA, Villarino MA, et al. Antibiotic levels in empyemic pleural fluid. Chest 2000; 117(6): 1734–9PubMedCrossRef
133.
go back to reference Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 Suppl. 5: 12–23PubMedCrossRef Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 Suppl. 5: 12–23PubMedCrossRef
134.
go back to reference Gill MA, Kern JW. Altered gentamicin distribution in ascitic patients. Am J Hosp Pharm 1979; 36(12): 1704–6PubMed Gill MA, Kern JW. Altered gentamicin distribution in ascitic patients. Am J Hosp Pharm 1979; 36(12): 1704–6PubMed
135.
go back to reference Lanao JM, Dominguez-Gil A, Macias JG, et al. The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 1980; 18(2): 57–61PubMed Lanao JM, Dominguez-Gil A, Macias JG, et al. The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 1980; 18(2): 57–61PubMed
136.
go back to reference Sampliner R, Perrier D, Powell R, et al. Influence of ascites on tobramycin pharmacokinetics. J Clin Pharmacol 1984; 24(1): 43–6PubMed Sampliner R, Perrier D, Powell R, et al. Influence of ascites on tobramycin pharmacokinetics. J Clin Pharmacol 1984; 24(1): 43–6PubMed
137.
go back to reference Lewis GP, Jusko WJ. Pharmacokinetics of ampicillin in cirrhosis. Clin Pharmacol Ther 1975; 18(4): 475–84PubMed Lewis GP, Jusko WJ. Pharmacokinetics of ampicillin in cirrhosis. Clin Pharmacol Ther 1975; 18(4): 475–84PubMed
138.
go back to reference Benoni G, Arosio E, Raimondi MG, et al. Distribution of ceftazidime in ascitic fluid. Antimicrob Agents Chemother 1984; 25(6): 760–3PubMedCrossRef Benoni G, Arosio E, Raimondi MG, et al. Distribution of ceftazidime in ascitic fluid. Antimicrob Agents Chemother 1984; 25(6): 760–3PubMedCrossRef
139.
go back to reference el Touny M, el Guinaidy MA, Abdel Barry M, et al. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites. J Antimicrob Chemother 1991; 28(1): 95–100PubMedCrossRef el Touny M, el Guinaidy MA, Abdel Barry M, et al. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites. J Antimicrob Chemother 1991; 28(1): 95–100PubMedCrossRef
140.
go back to reference Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med 1984; 77(4C): 26–32PubMed Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med 1984; 77(4C): 26–32PubMed
141.
go back to reference Hary L, Andrejak M, Leleu S, et al. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol 1989; 36(6): 613–6PubMedCrossRef Hary L, Andrejak M, Leleu S, et al. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol 1989; 36(6): 613–6PubMedCrossRef
142.
go back to reference Hary L, Smail A, Ducroix JP, et al. Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin Pharmacol 1991; 5(9): 789–95PubMedCrossRef Hary L, Smail A, Ducroix JP, et al. Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin Pharmacol 1991; 5(9): 789–95PubMedCrossRef
143.
go back to reference el Touny M, el Guinaidy M, Abdel Barry M, et al. Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. J Antimicrob Chemother 1992; 30(3): 387–95PubMedCrossRef el Touny M, el Guinaidy M, Abdel Barry M, et al. Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. J Antimicrob Chemother 1992; 30(3): 387–95PubMedCrossRef
144.
go back to reference Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 1990; 26 Suppl. B: 61–7PubMedCrossRef Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 1990; 26 Suppl. B: 61–7PubMedCrossRef
145.
go back to reference Lugo G, Castaneda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19(3): 271–6PubMedCrossRef Lugo G, Castaneda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19(3): 271–6PubMedCrossRef
146.
go back to reference Rosenbaum GS, Klein NC, Cunha BA. Poststernotomy mediastinitis. Heart Lung 1990; 19(4): 371–2PubMed Rosenbaum GS, Klein NC, Cunha BA. Poststernotomy mediastinitis. Heart Lung 1990; 19(4): 371–2PubMed
147.
go back to reference Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135(3): 149–64PubMed Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135(3): 149–64PubMed
148.
go back to reference Worman LW. The role of fluid sequestration in the pathogenesis of mediastinitis. Am J Surg 1966; 111(6): 813–8PubMedCrossRef Worman LW. The role of fluid sequestration in the pathogenesis of mediastinitis. Am J Surg 1966; 111(6): 813–8PubMedCrossRef
149.
go back to reference Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50(1): 73–7PubMedCrossRef Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50(1): 73–7PubMedCrossRef
150.
151.
go back to reference Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995; 29(1): 15–28PubMedCrossRef Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995; 29(1): 15–28PubMedCrossRef
152.
go back to reference Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999; 44(3): 319–27PubMedCrossRef Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999; 44(3): 319–27PubMedCrossRef
153.
go back to reference Lesne-Hulin A, Bourget P, Le Bever H, et al. Therapeutic monitoring of teicoplanin in a severely burned patient. Ann Fr Anesth Reanim 1997; 16(4): 374–7PubMedCrossRef Lesne-Hulin A, Bourget P, Le Bever H, et al. Therapeutic monitoring of teicoplanin in a severely burned patient. Ann Fr Anesth Reanim 1997; 16(4): 374–7PubMedCrossRef
154.
go back to reference Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16(10): 824–8PubMedCrossRef Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16(10): 824–8PubMedCrossRef
155.
go back to reference Zaske DE, Chin T, Kohls PR, et al. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 1991; 12(1): 46–50PubMedCrossRef Zaske DE, Chin T, Kohls PR, et al. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 1991; 12(1): 46–50PubMedCrossRef
156.
go back to reference Zaske DE, Sawchuk RJ, Strate RG. The necessity of increased doses of amikacin in burn patients. Surgery 1978; 84(5): 603–8PubMed Zaske DE, Sawchuk RJ, Strate RG. The necessity of increased doses of amikacin in burn patients. Surgery 1978; 84(5): 603–8PubMed
157.
go back to reference Loirat P, Rohan J, Baillet A, et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 1978; 299(17): 915–9PubMedCrossRef Loirat P, Rohan J, Baillet A, et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 1978; 299(17): 915–9PubMedCrossRef
158.
go back to reference Adam D, Zellner PR, Koeppe P, et al. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. J Antimicrob Chemother 1989; 24 Suppl. B: 121–9PubMedCrossRef Adam D, Zellner PR, Koeppe P, et al. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. J Antimicrob Chemother 1989; 24 Suppl. B: 121–9PubMedCrossRef
159.
go back to reference Walstad RA, Aanderud L, Thurmann-Nielsen E. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur J Clin Pharmacol 1988; 35(5): 543–9PubMedCrossRef Walstad RA, Aanderud L, Thurmann-Nielsen E. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur J Clin Pharmacol 1988; 35(5): 543–9PubMedCrossRef
160.
go back to reference Yoshida T, Homma K, Fujioka H, et al. Fundamental and clinical studies on meropenem in burn infections. J Chemother 1993; 5 Suppl. 1: 142–3 Yoshida T, Homma K, Fujioka H, et al. Fundamental and clinical studies on meropenem in burn infections. J Chemother 1993; 5 Suppl. 1: 142–3
161.
go back to reference Friedrich LV, White RL, Kays MB, et al. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 1991; 35(1): 57–61PubMedCrossRef Friedrich LV, White RL, Kays MB, et al. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 1991; 35(1): 57–61PubMedCrossRef
162.
go back to reference Brater DC, Bawdon RE, Anderson SA, et al. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986; 39(6): 631–4PubMedCrossRef Brater DC, Bawdon RE, Anderson SA, et al. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986; 39(6): 631–4PubMedCrossRef
163.
go back to reference Garrelts JC, Peterie JD. Altered vancomycin dose vs serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44(1): 9–13PubMedCrossRef Garrelts JC, Peterie JD. Altered vancomycin dose vs serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44(1): 9–13PubMedCrossRef
164.
go back to reference Rybak MJ, Albrecht LM, Berman JR, et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 34(5): 792–5PubMedCrossRef Rybak MJ, Albrecht LM, Berman JR, et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 34(5): 792–5PubMedCrossRef
165.
go back to reference Potel G, Moutet J, Bernareggi A, et al. Pharmacokinetics of teicoplanin in burn patients. Scand J Infect Dis Suppl 1990; 72: 29–34PubMed Potel G, Moutet J, Bernareggi A, et al. Pharmacokinetics of teicoplanin in burn patients. Scand J Infect Dis Suppl 1990; 72: 29–34PubMed
166.
go back to reference Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37(3): 545–53PubMedCrossRef Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37(3): 545–53PubMedCrossRef
167.
go back to reference Garrelts JC, Jost G, Kowalsky SF, et al. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996; 40(5): 1153–6PubMed Garrelts JC, Jost G, Kowalsky SF, et al. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996; 40(5): 1153–6PubMed
168.
go back to reference Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther 1990; 48(2): 130–7PubMedCrossRef Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther 1990; 48(2): 130–7PubMedCrossRef
169.
go back to reference Bourget P, Lesne-Hulin A, Le Reveille R, et al. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996; 40(1): 139–45PubMed Bourget P, Lesne-Hulin A, Le Reveille R, et al. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996; 40(1): 139–45PubMed
170.
go back to reference Lesne-Hulin A, Bourget P, Ravat F, et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. Eur J Clin Pharmacol 1999; 55(7): 515–9PubMedCrossRef Lesne-Hulin A, Bourget P, Ravat F, et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. Eur J Clin Pharmacol 1999; 55(7): 515–9PubMedCrossRef
171.
go back to reference Weinbren MJ. Pharmacokinetics of antibiotics in burns patients. J Antimicrob Chemother 2001; 47(5): 720PubMedCrossRef Weinbren MJ. Pharmacokinetics of antibiotics in burns patients. J Antimicrob Chemother 2001; 47(5): 720PubMedCrossRef
172.
go back to reference Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997; 18(2): 116–24PubMedCrossRef Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997; 18(2): 116–24PubMedCrossRef
173.
go back to reference Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns 1992; 18(5): 355–61PubMedCrossRef Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns 1992; 18(5): 355–61PubMedCrossRef
174.
go back to reference Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992; 14(2): 458–63PubMedCrossRef Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992; 14(2): 458–63PubMedCrossRef
175.
go back to reference Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg 1996; 172(6A): 20–5SCrossRef Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg 1996; 172(6A): 20–5SCrossRef
176.
go back to reference Lipman J, Scribante J, Gous AG, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42(9): 2235–9PubMed Lipman J, Scribante J, Gous AG, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42(9): 2235–9PubMed
177.
go back to reference Olsen NV. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Dan Med Bull 1998; 45(3): 282–97PubMed Olsen NV. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Dan Med Bull 1998; 45(3): 282–97PubMed
178.
go back to reference Lass NA, Glock D, Goldberg LI. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 1988; 78(5 Pt 1): 1310–5PubMedCrossRef Lass NA, Glock D, Goldberg LI. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 1988; 78(5 Pt 1): 1310–5PubMedCrossRef
179.
go back to reference Ludens JH, Hook JB, Brody MJ, et al. Enhancement of renal blood flow by furosemide. J Pharmacol Exp Ther 1968; 163(2): 456–60PubMed Ludens JH, Hook JB, Brody MJ, et al. Enhancement of renal blood flow by furosemide. J Pharmacol Exp Ther 1968; 163(2): 456–60PubMed
180.
go back to reference Ichai C, Passeron C, Carles M, et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med 2000; 28(5): 1329–35PubMedCrossRef Ichai C, Passeron C, Carles M, et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med 2000; 28(5): 1329–35PubMedCrossRef
181.
go back to reference Ichai C, Soubielle J, Carles M, et al. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: a single-blind randomized study. Crit Care Med 2000; 28(4): 921–8PubMedCrossRef Ichai C, Soubielle J, Carles M, et al. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: a single-blind randomized study. Crit Care Med 2000; 28(4): 921–8PubMedCrossRef
182.
go back to reference Moellering Jr RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Annals of Internal Medicine 1981; 94: 343–6PubMed Moellering Jr RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Annals of Internal Medicine 1981; 94: 343–6PubMed
183.
184.
go back to reference Kaojarern S, Maoleekoonpairoj S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother 1989; 33(8): 1406–8PubMedCrossRef Kaojarern S, Maoleekoonpairoj S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother 1989; 33(8): 1406–8PubMedCrossRef
185.
go back to reference Tod M, Lortholary O, Seytre D, et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 1998; 42(4): 849–56PubMed Tod M, Lortholary O, Seytre D, et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 1998; 42(4): 849–56PubMed
186.
go back to reference Zeitany RG, el Saghir NS, Santhosh-Kumar CR, et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34(5): 702–8PubMedCrossRef Zeitany RG, el Saghir NS, Santhosh-Kumar CR, et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34(5): 702–8PubMedCrossRef
187.
go back to reference Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40(5): 1242–7PubMed Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40(5): 1242–7PubMed
188.
go back to reference Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 2001; 33(3): 222–6PubMedCrossRef Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 2001; 33(3): 222–6PubMedCrossRef
189.
go back to reference Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish Study Group. Eur J Clin Microbiol Infect Dis 1997; 16(11): 797–802PubMedCrossRef Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish Study Group. Eur J Clin Microbiol Infect Dis 1997; 16(11): 797–802PubMedCrossRef
190.
go back to reference Cirillo M, Anastasio P, Spitali L, et al. Effects of a meat meal on renal sodium handling and sodium balance. Miner Electrolyte Metab 1998; 24(4): 279–84PubMedCrossRef Cirillo M, Anastasio P, Spitali L, et al. Effects of a meat meal on renal sodium handling and sodium balance. Miner Electrolyte Metab 1998; 24(4): 279–84PubMedCrossRef
191.
go back to reference Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49(8): 3550–3PubMedCrossRef Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49(8): 3550–3PubMedCrossRef
192.
go back to reference Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999; 72: S24–8PubMed Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999; 72: S24–8PubMed
193.
go back to reference Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45(8): 929–34PubMedCrossRef Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45(8): 929–34PubMedCrossRef
194.
go back to reference Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27(9): 808–14PubMedCrossRef Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27(9): 808–14PubMedCrossRef
195.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRef
196.
go back to reference Mohler JL, Barton SD, Blouin RA, et al. The evaluation of creatinine clearance in spinal cord injury patients. J Urol 1986; 136(2): 366–9PubMed Mohler JL, Barton SD, Blouin RA, et al. The evaluation of creatinine clearance in spinal cord injury patients. J Urol 1986; 136(2): 366–9PubMed
197.
go back to reference Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002; 20(5): 326–32PubMedCrossRef Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002; 20(5): 326–32PubMedCrossRef
198.
go back to reference Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. Clin Infect Dis 2003; 36(8): 1013–7PubMedCrossRef Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. Clin Infect Dis 2003; 36(8): 1013–7PubMedCrossRef
199.
go back to reference Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28(7): 936–42PubMedCrossRef Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28(7): 936–42PubMedCrossRef
200.
go back to reference Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114(3): 194–8PubMedCrossRef Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114(3): 194–8PubMedCrossRef
201.
go back to reference Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28(12): 1335–9PubMed Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28(12): 1335–9PubMed
202.
go back to reference van Lent-Evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21(1): 63–73PubMedCrossRef van Lent-Evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21(1): 63–73PubMedCrossRef
Metadata
Title
Antimicrobial Therapy in Critically Ill Patients
A Review of Pathophysiological Conditions Responsible for Altered Disposition and Pharmacokinetic Variability
Authors
Dr Federico Pea
Pierluigi Viale
Mario Furlanut
Publication date
01-10-2005
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2005
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200544100-00002

Other articles of this Issue 10/2005

Clinical Pharmacokinetics 10/2005 Go to the issue

Original Research Article

Quantification of Lean Bodyweight